Estimated costs attributable to events of "out-of-temperature" in the stockpiling of hexavalent vaccines occurring in Italy

Author: Silvestri R & Marchetti

Abstract

Antigens contained in vaccines are inherently unstable biologically; such a characteristic is conferred by their three-dimensional structure. Preserving the ability of the vaccines to protect against disease is necessary to ensure the supervision and monitoring of all steps of the cold chain. DTPa-HBV-IPV/Hib vaccine (Infanrix hexaTM, GSK Vaccines, Belgium) is designed to prevent disease due to diphtheria, tetanus, pertussis (DTP), hepatitis B virus (HBV), poliomyelitis and Haemophilus influenzae type b (Hib); it was first licensed for use in Europe in 2000 and is currently licensed in at least 95 countries. Since October 2013, more than 102 million doses of GSK's DTPa-HBV-IPV/Hib vaccine have been distributed globally, with nearly 15 million doses distributed in Italy. DTPa-HBV-IPV/Hib components are stable up to a temperature of 25°C for 72 hours. Lacking of officially approved stability data may generate some concern in case of cold chain accidents.

About

Type Journal article
Language English
Country Italy
Link http://www.ncbi.nlm.nih.gov/pubmed/26661911
PubMed URL http://www.ncbi.nlm.nih.gov/pubmed/26661911
Journal Ann Ig.
Volume 27
Year 2016
Disease , Hepititis B , Diphtheria , Haemophilus influenzae , Pertussis , Tetanus
Added by Moderator
Added on 19 January 2016 06:45:32
Hits: 453
Rating Summary:
0 based on 0 votes
Add to Favourites